On the pricing page of Plum's website, the pitch is almost defiant in its simplicity: employee health coverage starting at roughly a dollar a month, with pre-existing conditions, mental health, vision, and dental folded in for workers and their families [Plum website]. In a country where corporate health insurance has historically been the preserve of large enterprises and their tier-one carriers, that price point is the wedge. Plum is betting that India's small and mid-sized employers, the ones that have never offered group cover before, will be the ones to define the next decade of the category.
The Bengaluru company, founded in 2019 by Abhishek Poddar and Saurabh Arora, closed a $20.6 million Series B in March led by Peak XV Partners, the firm formerly known as Sequoia India [Reuters, March 2026]. That brings total disclosed funding to roughly $41.2 million across four rounds [Tracxn]. Moneycontrol pegged the round at Rs 193 crore and framed it as growth capital to scale the employee benefits platform [Moneycontrol].
The bet
Plum sells group health insurance to businesses, then administers the experience for the employee through its own software: enrollment, claims, telehealth, wellness sessions, the lot [Crunchbase]. The B2B2C structure matters. The employer is the buyer and the payer, but Plum owns the relationship with the end user, which is where retention, cross-sell, and data accumulate. The company says it covers pre-existing diseases, mental health, vision, and dental from day one [Plum website], a feature set that traditional Indian group policies have historically treated as add-ons or carve-outs.
In the last year Plum extended beyond pure insurance distribution. It launched a healthcare arm offering diagnostics, teleconsultations, and what it describes as AI-powered health tracking, funded with Rs 200 crore from internal reserves [Moneycontrol]. That is a meaningful capital commitment from a company that has raised $41 million total, and it signals where management thinks the margin pool sits: not in placing the policy, but in everything that happens after.
Why it could be big
India's group health market has structural tailwinds that do not require any heroic assumptions. Employer-sponsored cover is still a small share of the working population, regulatory pressure on insurers to broaden distribution has eased the path for digital intermediaries, and the SMB segment, Plum's core, has been historically underwritten by no one. A platform that can onboard a 40-person startup in a day and deliver a usable mobile claims experience is solving a real procurement headache.
The cap table reflects that thesis. Tiger Global led the $15.6 million Series A in May 2021 [TechCrunch, May 2021]. Peak XV led the Series B [Reuters, March 2026]. Earlier backers include Sequoia Surge, which incubated the company, alongside Tanglin Venture Partners, Incubate Fund, and GMO Venture Partners. That is a roster of investors who have underwritten Indian fintech and insurtech across multiple cycles, and their continued participation through a tougher funding environment is itself a data point.
Series A (May 2021) | 15.6 | $M
Series B (Mar 2026) | 20.6 | $M
Total disclosed | 41.2 | $M
Healthcare arm investment | 24 | $M
The healthcare arm figure converts Rs 200 crore at recent rates, estimated.
The team and the traction
Poddar, who runs the company, and Arora, the technical co-founder, have been building Plum since 2019. The most interesting operating disclosure of the past cycle is not the round size but the financial posture behind it. Entrackr reported that Plum closed its first full year of EBITDA and cash flow profitability [Entrackr], a rare claim from an Indian insurtech of this stage. The company also says it is running a customer Net Promoter Score of 79 [LinkedIn, 2026], which, if it holds up at scale, would put it well above industry norms for health insurance, a category not historically loved by its users.
Based on the Series B size and Peak XV's lead, post-money valuation lands somewhere near $123 million (estimated). That is a measured step up from the Series A vintage, which is the kind of mark-to-market most Indian growth-stage companies are getting right now.
What the bears say, what the bulls answer
The competitive set is the obvious pressure point. Onsurity, Nova Benefits, SecureNow, and Loop Health are all chasing the same SMB employer with broadly similar pitches: digital onboarding, mobile-first claims, wellness bundled in. Loop in particular has raised aggressively and pushes hardest on the in-house clinical layer. Bears will argue that group health is a distribution game, that price competition compresses unit economics, and that the eventual winner is whoever has the cheapest customer acquisition, not the slickest app.
The bull answer, supported by what Plum has disclosed, is that the company is the one in the set claiming a profitable year [Entrackr] while also self-funding a healthcare delivery arm [Moneycontrol]. If both hold, Plum is compounding on its own cash rather than burning to defend share, which changes the shape of the race. The NPS figure [LinkedIn, 2026], if independently sustained, also suggests retention economics that could let the company spend less per renewal than competitors fighting for the same logos every year.
What to watch
Three things over the next twelve months. First, whether the healthcare arm starts producing disclosed revenue, which would validate the cross-sell thesis behind the Rs 200 crore commitment. Second, whether Plum publishes audited FY figures that confirm the profitability claim at scale rather than at a single year-end snapshot. Third, whether Peak XV's lead pulls in a growth-stage co-investor for a follow-on, which is usually how Indian Series B winners signal they are setting up for a pre-IPO round.
The broader question for readers watching emerging-market capital flows: if Plum can run profitably while still growing into a market this underpenetrated, does the next wave of Indian insurtech get funded on cash flow rather than on cap-table dilution? That would be a different game than the one Tiger Global underwrote in 2021. Worth watching who blinks first.